APOA1: a Protein with Multiple Therapeutic Functions.

Cochran, BJ; Ong, K-L; Manandhar, B; Rye, K-A

APOA1: a Protein with Multiple Therapeutic Functions.

Cochran, BJ Ong, K-L Manandhar, B

Rye, K-A

Permalink

Publisher:: CURRENT MEDICINE GROUP
Publication Type:: Journal Article
Citation:: Curr Atheroscler Rep, 2021, 23, (3), pp. 11
Issue Date:: 2021-02-16

Closed Access

	Filename	Description	Size
	Cochran2021_Article_APOA1AProteinWithMultipleThera.pdf	Published version	524.88 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Cochran, BJ
dc.contributor.author	Ong, K-L
dc.contributor.author	Manandhar, B https://orcid.org/0000-0003-1276-6954
dc.contributor.author	Rye, K-A
dc.date.accessioned	2022-06-18T21:10:44Z
dc.date.available	2021-01-08
dc.date.available	2022-06-18T21:10:44Z
dc.date.issued	2021-02-16
dc.identifier.citation	Curr Atheroscler Rep, 2021, 23, (3), pp. 11
dc.identifier.issn	1523-3804
dc.identifier.issn	1534-6242
dc.identifier.uri	http://hdl.handle.net/10453/158240
dc.description.abstract	PURPOSE OF THE REVIEW: Apolipoprotein (APO) A1, the main apolipoprotein of plasma high-density lipoproteins (HDLs), has several well documented cardioprotective functions. A number of additional potentially beneficial functions of APOA1 have recently been identified. This review is concerned with the therapeutic potential of all of these functions in multiple disease states. RECENT FINDINGS: Knowledge of the beneficial functions of APOA1 in atherosclerosis, thrombosis, diabetes, cancer, and neurological disorders is increasing exponentially. These insights have led to the development of clinically relevant peptides and APOA1-containing, synthetic reconstituted HDL (rHDL) preparations that mimic the functions of full-length APOA1. APOA1 is a multifunctional apolipoprotein that has therapeutic potential in several diseases. Translation of this knowledge into the clinic is likely to be dependent on the efficacy and bioavailability of small peptides and synthetic rHDL preparations that are currently under investigation, or in development.
dc.format	Electronic
dc.language	eng
dc.publisher	CURRENT MEDICINE GROUP
dc.relation.ispartof	Curr Atheroscler Rep
dc.relation.isbasedon	10.1007/s11883-021-00906-7
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1102 Cardiorespiratory Medicine and Haematology
dc.subject.classification	Cardiovascular System & Hematology
dc.subject.mesh	Apolipoprotein A-I
dc.subject.mesh	Atherosclerosis
dc.subject.mesh	Humans
dc.subject.mesh	Lipoproteins, HDL
dc.subject.mesh	Neoplasms
dc.subject.mesh	Humans
dc.subject.mesh	Neoplasms
dc.subject.mesh	Lipoproteins, HDL
dc.subject.mesh	Apolipoprotein A-I
dc.subject.mesh	Atherosclerosis
dc.title	APOA1: a Protein with Multiple Therapeutic Functions.
dc.type	Journal Article
utslib.citation.volume	23
utslib.location.activity	United States
utslib.for	1102 Cardiorespiratory Medicine and Haematology
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	closed_access	*
dc.date.updated	2022-06-18T21:10:42Z
pubs.issue	3
pubs.publication-status	Published online
pubs.volume	23
utslib.citation.issue	3

Abstract:

PURPOSE OF THE REVIEW: Apolipoprotein (APO) A1, the main apolipoprotein of plasma high-density lipoproteins (HDLs), has several well documented cardioprotective functions. A number of additional potentially beneficial functions of APOA1 have recently been identified. This review is concerned with the therapeutic potential of all of these functions in multiple disease states. RECENT FINDINGS: Knowledge of the beneficial functions of APOA1 in atherosclerosis, thrombosis, diabetes, cancer, and neurological disorders is increasing exponentially. These insights have led to the development of clinically relevant peptides and APOA1-containing, synthetic reconstituted HDL (rHDL) preparations that mimic the functions of full-length APOA1. APOA1 is a multifunctional apolipoprotein that has therapeutic potential in several diseases. Translation of this knowledge into the clinic is likely to be dependent on the efficacy and bioavailability of small peptides and synthetic rHDL preparations that are currently under investigation, or in development.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/158240